This approach provided promising results in targeting tumor related angiogenesis and led to the clinical approval of some of these agents, including bevacizumab, a monoclonal antibody targeting VEGFA which is approved for use in the treatment of multiple solid tumor types, such as colorectal, lung, renal, cervical, ovarian cancer, and glioblastoma, either alone or in combination with other drugs (30). The gene discussed is VEGFA; the disease is neoplasm.